FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Celldex Therapeutics, Inc. Shares Surge After Positive Trial Data”
Celldex Therapeutics, Inc. (NASDAQ: CLDX) climbed over 31% in premarket trading after the company announced updated data from its ongoing, open label Phase 1b clinical trial of CDX-0159
CDX-0159 is a humanized, monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity in patients with antihistamine refractory cold urticaria and symptomatic dermographism, the two most common forms of chronic inducible urticaria.
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer.
For more information, please visit: Celldex Therapeutics, Inc.
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.